BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24322486)

  • 1. Advances in the diagnosis and treatment of eosinophilia.
    Helbig G
    Curr Opin Hematol; 2014 Jan; 21(1):3-7. PubMed ID: 24322486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
    Gotlib J; Cross NC; Gilliland DG
    Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophilic myeloid neoplasms.
    Noel P; Mesa RA
    Curr Opin Hematol; 2013 Mar; 20(2):157-62. PubMed ID: 23385615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies.
    Gotlib J
    Curr Opin Hematol; 2010 Mar; 17(2):117-24. PubMed ID: 20071982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypereosinophilic syndromes.
    Roufosse FE; Goldman M; Cogan E
    Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypereosinophilic syndromes: pathogenic and therapeutic up-to-date].
    Kahn JE; Grandpeix-Guyodo C; Ackermann F; Charles P; Legrand F; Blétry O
    Rev Med Interne; 2010 Apr; 31(4):268-76. PubMed ID: 20303627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypereosinophilic syndrome and proliferative diseases.
    Ionescu MA; Wang L; Janin A
    Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.
    Valent P; Klion AD; Horny HP; Roufosse F; Gotlib J; Weller PF; Hellmann A; Metzgeroth G; Leiferman KM; Arock M; Butterfield JH; Sperr WR; Sotlar K; Vandenberghe P; Haferlach T; Simon HU; Reiter A; Gleich GJ
    J Allergy Clin Immunol; 2012 Sep; 130(3):607-612.e9. PubMed ID: 22460074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
    Lierman E; Cools J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypereosinophilia of the blood. II. Classification. Benign essential hypereosinophilia. Eosinophilia caused by systemic eosinophilic hemopathies].
    Lovisetto P; Manachino D; Biarese V; Marchi L; Andrione P
    Minerva Med; 1985 May; 76(22-23):1049-53. PubMed ID: 4011004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in diagnosis and treatment of eosinophilia.
    Sheikh J; Weller PF
    Curr Opin Hematol; 2009 Jan; 16(1):3-8. PubMed ID: 19057198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis of non-parasitic hypereosinophilia].
    Kahn JE; Girszyn N; Blétry O
    Presse Med; 2006 Jan; 35(1 Pt 2):144-52. PubMed ID: 16462679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clonal eosinophilia revealed by recurrent Staphylococcus aureus infection].
    Vandenbos F; Figueredo M; Dumon-Gubeno MC; Nicolle I; Tarhini A; Medioni LD; Naman H; Mouroux J
    Rev Pneumol Clin; 2011 Jun; 67(3):167-9. PubMed ID: 21665081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.